No one would dispute that safeguarding the benefits of antibiotics for
treatment of human diseases is paramount. But is banning on their use
as growth promoters a wise move? What can Europe expect now? And what
can we do to smooth the transition? Sarah Mellor joined some of the
world's experts in the Netherlands to find out…
This article can also be found at Feed Mix, volume 13, no. 2
FM_13.2_2.pdf